Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Invex Therapeutics.
RELATED STOCKHEAD STORIES
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
News
Small caps were still raising money in May; health beat resources again
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target
News
Rise and Shine: What you need to know before the ASX opens
Escrow Watch
Escrow Watch: Watch out for these bundles of stock about to land on the ASX
Health & Biotech
WA biotechs are booming; now government wants to make the state a life sciences hub
Health & Biotech
Biotech: GMV finishes trials needed to enter Chinese market; shares rally
Health & Biotech
Biotech: Invex hopes to blow minds with hypertension drug results
IPO Watch
IPO Watch: These are the top ASX debutantes of 2019
Health & Biotech
Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye
Health & Biotech
The science behind Invex Therapeutics could be used to help astronauts get to Mars
Health & Biotech
Health: Immutep gains 12% on promising melanoma treatment
IPO Watch
IPO Watch: Tech and pot floats still on fire
IPO Watch
